FDA Looks to Raise Survival Bar for Cancer Drug Approvals in New Draft Guidance

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new guidance follows the surprising return of CBER Head Vinay Prasad, who has previously argued for prioritizing OS.